Moderna's mRNA flu shot, 27% more effective than standard vaccines, wins U.S. approval

Moderna's mRNA flu vaccine cleared the FDA this week, the first time the agency has approved a flu shot built on the platform that powered the COVID-19 vaccines. The trial result was a 27% efficacy edge over a standard-dose flu shot in adults 50 and older. The number that will outlast the trial is the production cycle: two to three months, versus about six for the egg-based, cell-culture, and recombinant shots that have defined U.S. flu vaccination for more than 70 years.

The Phase 3 result was published in the New England Journal of Medicine alongside the approval (NEJM). Moderna's mFlusiva reduced the likelihood of influenza illness by 27% compared with a standard-dose comparator in adults 50 and older, the population studied. The FDA cleared the vaccine for two age brackets: adults 50 to 64, and adults 65 and older, with the older bracket contingent on a post-approval confirmatory trial (FDA/CBER review).

Traditional flu vaccines grow the target virus in chicken eggs, mammalian cell cultures, or recombinant systems, a process that locks in which strains to target roughly half a year before flu season starts. Moderna's mRNA vaccine instead carries a synthetic genetic instruction that teaches the recipient's cells to produce a viral protein, which the immune system then learns to recognize. Redesigning the molecule to chase a different strain takes weeks, not months (Scientific American; Moderna IR).

The cycle-time difference has a second-order effect the wire copy will not reach. If the predicted strains turn out to be the wrong ones, an egg-based year is locked in: the wrong recipe, distributed at scale, with no path to a mid-season update. An mRNA platform can, in principle, be redesigned and remanufactured within a single flu season once surveillance identifies what is actually spreading.

The FDA initially declined to review Moderna's application earlier in 2025, then reversed that decision about a week later (BioPharma Dive). The reversal left the regulatory record short on an outside explanation, but the approval itself came with a standard set of conditions: the 50-to-64 indication cleared, the 65-and-up indication contingent on a further trial, and the post-market safety monitoring that accompanies any new vaccine.

Health and Human Services Secretary Robert F. Kennedy Jr. is a vocal critic of mRNA vaccines, and HHS has canceled millions of dollars in mRNA vaccine research funding in the same period the approval was issued (Scientific American). A vaccine cleared on its trial data, and a department that is simultaneously pulling back from the platform that produced it, now sit on the same news cycle.

U.S. seasonal flu kills between roughly 6,300 and 52,000 people per year, per CDC figures cited in the source, and the 50-and-older brackets are the most exposed (Scientific American). The 27% efficacy edge in adults 50 and over is the first direct head-to-head result of its kind for an mRNA flu vaccine in that population.

What the approval does not extend is coverage to younger adults or to children. Those populations would require separate review and a separate efficacy and safety package, and the source does not place that work on a near-term clock.

The next test is whether Moderna's confirmatory trial in the 65-and-up group, and the next phase of mRNA flu candidates from Moderna and others, can show the same edge in younger cohorts and across seasons. The FDA's clearance is scoped, conditional, and tied to data still to come. The cycle-time mechanism is the part the platform now has to defend in the field.